ZoBio

ZoBio is a private, self-funded drug discovery CRO founded in 2006, headquartered in Leiden, Netherlands. The company has established itself as a pioneer in fragment-based drug discovery over two decades, offering tailored research programs from target validation to lead compound generation. Its core technology platform originated from the proprietary Target Immobilized NMR Screening (TINS) method, which it has expanded into a comprehensive suite of biophysical and biochemical assays. ZoBio operates as a service provider, generating revenue through collaborative R&D projects with pharmaceutical and biotechnology companies.

Integrated fragment-based drug discovery (FBDD) platform anchored by proprietary Target Immobilized NMR Screening (TINS). Includes protein science (challenging targets, isotopic labeling), biophysical assays (SPR, MST, thermal shift), structural biology (X-ray, NMR), biochemical assays, and medicinal chemistry for hit-to-lead optimization.

ZoBio competes in the specialized FBDD segment against other boutique CROs (e.g., Vernalis, Fragmenta) and the fragment-based screening divisions of large CROs (e.g., Charles River, Evotec). Its differentiation lies in its proprietary TINS technology, deep expertise in membrane proteins, and an integrated, collaborative service model. It avoids direct competition with AI-first drug discovery companies by focusing on experimental biophysical validation.